Carmell Therapeutics President & CEO, Randy Hubbell, to Present at Biotech Showcase™ 2019 in San Francisco
Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced its President and CEO, Randy Hubbell, will deliver a corporate presentation at Biotech Showcase™ 2019, on Tuesday, January 8, 2019 at 3:15 PM PST at the Hilton San Francisco Union Square in the Franciscan C ballroom.
Hubbell will discuss Carmell’s latest milestones, including Phase III clinical trial plans for their flagship Bone Healing Accelerant product. He will also provide insights into the current state of the orthobiologics industry, including key differentiators, market opportunities and regulatory trends.
“We are very pleased that Carmell was chosen to present at Biotech Showcase and look forward to meeting with investors and key industry stakeholders in San Francisco this January,” said Randy Hubbell, Carmell’s President and CEO. “We particularly look forward to sharing the story of our technology, which represents a fundamental shift in medicine as it relates to enhanced healing mechanisms and discussing our robust regulatory pathway approach that delivers confidence and value to our end user stakeholders.”
Carmell’s proprietary PBM platform is based on biologically-active materials manufactured from human blood plasma, containing natural regenerative factors that promote healing in various clinical settings. Carmell has patented a process which allows for the controlled, staged release of regenerative factors to promote faster healing.
About Carmell Therapeutics
Carmell Therapeutics (Carmell) is addressing the burden of bone and tissue healing with its proprietary Plasma-based Bioactive Materials (PBM) technology, designed to improve patient outcomes and reduce health care costs. Carmell’s novel approach takes whole platelet-rich plasma, processes it in a manner that retains its regenerative properties, and delivers it to the injured site in a controlled-release capacity for faster, more effective healing. For more information, please visit www.carmellrx.com
About Carmell’s PBM Technology Platform
Carmell Therapeutics’ unique PBM technology platform can be delivered in multiple formats to the site of injury – from putties to pastes to surgical screws. A proprietary manufacturing process ensures safety and that bioactive regenerative factors are delivered in a time-released manner for optimal healing. Carmell currently has two PBM products in development – a Bone Healing Accelerant and Tissue Healing Accelerant.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005455/en/